Ahmedabad: Zydus Lifesciences Ltd, a global healthcare company announced that it has entered into an agreement with CVS Caremark, a CVS Health company to add Zituvio, Zituvimet and Zituvimet XR (Sitagliptin | Sitagliptin and Metformin Hydrochloride) tablets to its template formulary.
CVS Caremark will add Zydus’ Zituvio and combination products to its template formulary starting January 1, 2025.
Zituvio and combination products include Zituvio (sitagliptin), Zituvimet (sitagliptin and metformin hydrochloride) and Zituvimet XR (sitagliptin and metformin hydrochloride) extended-release tablets. These three NDAs of Sitagliptin (base) and combination franchise have been approved by the USFDA earlier through the 505(b)(2) route.
The Zituvio range of products contain active ingredients sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Punit Patel, President & CEO Zydus Pharmaceuticals USA Inc., commented on the development, saying, "We are proud to have partnered with CVS Caremark, one of the most patient-centric healthcare solutions providers in the US, to further our commitment to improving access to high-quality medications to patients and meeting their healthcare needs with reduced outlays. This relationship is a strong validation of Zydus’ strategic investments in 505(b)(2) portfolio and will set the way for further strengthening our portfolio of differentiated products in the US market."
Metabolic and lifestyle conditions, such as diabetes have been a significant contributor to prescription drug growth over the last decade. According to IQVIA (MAT Aug-2023), U.S. market for DPP-IV inhibitors and their combinations is US$ 10 bn.
Zydus Lifesciences Ltd. is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. Zydus has been actively discovering and developing New Chemical Entities (NCEs) novel biologicals, several biosimilars and vaccines as a part of its innovation pipeline. Over the last decade, Zydus has introduced several products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals and biosimilars.
Read also: Zydus Lifesciences arm application for Menkes disease treatment gets USFDA priority review
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.